Also from this source

You just read:

Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation

News provided by

Recursion Pharmaceuticals

Jul 10, 2018, 07:00 ET